---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-095460"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2025-07-14T23:59:59+00:00"
generated_at: "2026-05-18T06:45:04.722843+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MiNK Therapeutics announces complete remission in testicular cancer and Phase 2 gastric cancer survival data

## Summary
- Complete and durable remission in metastatic testicular cancer patient after single infusion of agenT-797 plus nivolumab, per Nature's Oncogene publication.
- Phase 2 gastric cancer trial data showed immune activation, tumor infiltration, and survival beyond 12 months in checkpoint-refractory patients.
- Separate case report: 42% tumor reduction and >9 months progression-free survival in gastric cancer patient with single agenT-797 infusion plus nivolumab.
- Phase 2 trial (NCT06251973) actively enrolling with additional readouts expected.

## SEC filing metadata
- accession: 0000950170-25-095460
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2025-07-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000095017025095460/0000950170-25-095460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000095017025095460/inkt-20250711.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-095460
- JSON: https://secwatch.observer/filing/0000950170-25-095460.json
- Plain text: https://secwatch.observer/filing/0000950170-25-095460.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.